Federal Cannabis Rescheduling: What the Record Actually Shows

As of August 20, 2026, the record shows two different federal actions: a final rule effective April 28, 2026, covering a narrower category of marijuana-related drugs and medical-marijuana licensees, and a separate proposed rule to move general marijuana from schedule I to schedule III that was still proceeding through a hearing process. Rescheduling is not legalization.

By Cannible Editorial

2026-07-31

This is general information, not individualized legal, medical, business, or compliance advice. Consult a qualified professional about a personal or commercial decision.

The key distinction: final rule versus proposed rule

On May 21, 2024, the Department of Justice published a notice of proposed rulemaking that proposed transferring general marijuana from schedule I to schedule III under the Controlled Substances Act. A proposed rule is not a final rule. The proposal was subject to formal rulemaking on the record after an opportunity for a hearing. 3 4

On April 28, 2026, the Department of Justice issued a separate final rule, effective that same date. That final rule places in schedule III drug products containing marijuana that have been approved by the Food and Drug Administration. It also covers specified marijuana, marijuana extracts, delta-9-tetrahydrocannabinol and other compounds derived from the marijuana plant, excluding mature stalks and seeds, when they are included in an FDA-approved drug product or are subject to a state-issued license to manufacture, distribute, or dispense marijuana for medical purposes. 1

What happened in the general-marijuana proceeding

The general-marijuana proposal began on May 21, 2024. DEA published a notice of hearing on August 29, 2024, announcing a hearing that was to begin on December 2, 2024. On April 28, 2026, DEA withdrew that earlier hearing notice and terminated the related proceedings. The withdrawal was a procedural action; it was not a final decision adopting the proposed transfer. 2 3

On April 28, 2026, DEA published a new notice of hearing concerning the proposed rule. That notice stated that the hearing would commence on June 29, 2026, and conclude no later than July 15, 2026, subject to possible changes announced by the administrative law judge. A notice that a hearing will be held is not the same as a completed agency action or a final rule. 2

The supplied record does not include a final rule transferring general marijuana to schedule III. It therefore does not support describing that broader rescheduling as completed as of August 20, 2026. 2 3

What the April 28 final rule actually covers

The final rule is not a blanket placement of all marijuana in schedule III. Its stated scope is tied to FDA-approved drug products and to marijuana or marijuana-containing products covered by a state medical-marijuana license. The final rule therefore must not be treated as interchangeable with the broader May 21, 2024, proposal concerning general marijuana. 1 3 4

The FDA record says that, as of the material supplied, the agency had not approved a marketing application for cannabis to treat any disease or condition. It also says FDA had approved one cannabis-derived and three cannabis-related drug products, available only by prescription from a licensed healthcare provider. The final rule’s reference to FDA-approved drug products should be read within that stated category, not as an approval of cannabis generally. 5 1

The specific federal process created by the final rule

The April 28, 2026, final rule adds the covered drugs to the substances that may be imported or exported only pursuant to a permit. It also establishes an expedited registration process under 21 CFR part 1301 for entities holding state medical-marijuana licenses. That process enables those entities to manufacture, distribute, or dispense marijuana for medical purposes under federal law, subject to the process’s federal requirements and consistency with the Single Convention on Narcotic Drugs. 1

This is a specific federal registration pathway for entities holding the identified state medical-marijuana licenses. It is not evidence that every cannabis business is eligible, that every cannabis product is covered, or that a company’s own announcement creates an industry-wide legal requirement. 1

What rescheduling does not establish in this record

Rescheduling is not legalization. In the May 21, 2024, proposed rule, DOJ expressly stated that, if general marijuana were transferred to schedule III, the manufacture, distribution, dispensing, and possession of marijuana would remain subject to applicable criminal prohibitions of the Controlled Substances Act. The same proposal stated that drugs containing a substance within the CSA definition of marijuana would remain subject to applicable Federal Food, Drug, and Cosmetic Act prohibitions. 4

That conditional statement belongs to the proposed general transfer and should not be mistaken for a statement that the broader transfer became final. Separately, the final rule’s text supplied here does not state outcomes concerning criminal penalties outside its covered categories. 4 1

The supplied scheduling record does not describe employment law, workplace drug testing, taxation, interstate commerce generally, banking, patient access generally, or the operation of any state cannabis program. A federal action is not a state law, and nothing in this record establishes what any particular state permits or requires. Those questions require separate legal and regulatory analysis rather than an inference from the schedule alone. 1 4

The practical takeaway

The April 28, 2026, final rule is real and effective, but its stated scope is narrower than general marijuana rescheduling. 1

The broader move from schedule I to schedule III was proposed on May 21, 2024, and proceeded through hearing notices dated August 29, 2024, and April 28, 2026; the supplied record does not show a final rule adopting it by August 20, 2026. 3 2

The final rule creates a defined federal registration process for entities holding state medical-marijuana licenses and imposes a permit requirement for importing or exporting covered drugs. 1

Neither the final rule described here nor the pending proposed rule supports calling cannabis federally legalized or resolving employment, testing, taxation, banking, interstate-commerce, patient-access, or state-law questions. 1 4